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Glossary of key terms and abbreviations  
 
 
List of Abbreviations 
 
BBV Blood-borne virus 
HCV Hepatitis C Virus 
HIV Human Immunodeficiency Virus 
HBV Hepatitis B Virus 
ENSP Enhanced Needle and Syringe Programme 
OST Opiate Substitution Therapy 
SOP Standard Operating Procedure 
DAA Direct acting anti-viral 
PWID People who inject drugs 
NGO Nongovernmental organisation 
DBST Dry Blood Spot Test 
NHS National Health Service 
WHO World Health Organization 
CPD Continuing Professional Development 
POC Point of Care 
 
Key terms and definitions 
 
Stakeholder  Person or organisation who have a vested interest in the guidelines are 
considered stakeholders. 
HCV infection Active replication of HCV in the body. The biomarker of HCV infection is 
the presence of HCV RNA in the blood. 
Enhanced needle and 
syringe programmes 
Sites where sterile equipment to prepare and consume drugs are 
provided in addition to complimentary harm reduction and recovery 
services such as health and wellbeing clinics, advice on safer injecting 
practice, avoiding and managing an overdose and referrals to drug 
treatment and other health care services. 
HCV nurse specialist Clinical nurse specialist for nursing care and professional expert advice 
in relation to the prevention, testing, and treatment of individuals with 
Hepatitis C. 
Pathway Treatment pathways relate to several healthcare professionals working 
together to provide optimal care and treatment to a target population 
in a particular community setting (i.e. community drugs services, needle 
and syringe programmes, pharmacies and in-prison).  
HCV testing This term refers to various HCV testing means, typically dry blood spot 
testing, venepuncture or oral swabs. While oral swabs can only be used 
for HCV screening (i.e. identifying the presence of HCV antibodies), the 
dry blood spot test can be used for HCV antibody testing and HCV PCR 
testing, which is valuable if access to suitable veins or access to health 
care professionals skilled in conducting venepuncture is not possible. 
Point of care  A point of care test is a rapid testing technology that allows people to 
be tested and learn the results during the same visit. These tests can be 





performed where the patient is receiving care, which may be outside of 
a clinical setting.  
HCV Antibody Test A HCV antibody test determines the presence of antibodies to HCV 
generated by the immune system. It is typically the first test undertaken 
to examine whether a person has been exposed to HCV. 
HCV Antibody positive 
Test Result 
A positive HCV antibody test result indicates that the person has been 
infected with HCV at some point in time, and typically leads to the 
person requiring further HCV confirmatory blood tests. 
HCV PCR blood test The HCV PCR blood test determines the presence of the HCV viral load 
(HCV RNA) and indicates whether HCV is still present (i.e. leading to a 
positive HCV diagnosis). 
RNA is the HCV’s genetic material. 
Dry Blood Spot Test This is a form of biosampling where finger prick blood samples are 
blotted and dry on filter paper, and thereafter tested for the presence 
of HCV antibodies, and/or HCV PCR test can also be completed on this 
blood sample. 
Venepuncture The puncture of a vein as part of a medical procedure, typically to 
withdraw a blood sample or for an intravenous injection. 
Residential officer 
(prison officer – 
residential) 
A prison officer (Scotland) who is predominantly based in the residential 
halls, and whose role is to support people residing in prison on a day-to-
day basis to facilitate case management. 
Case management Case management is a collaborative process that assesses, plans, 
implements, coordinates, monitors, and evaluates the options and 
services required to meet the a service user’s health and human service 
needs. 
Healthcare facilitator or 
HCV champion 
This is a person who is tasked to facilitate meeting specific objectives 
such as effectively promoting HCV testing and treatment, in a HCV 
treatment pathway. The healthcare facilitator or HCV champion may 
contribute to oversight, or facilitate communication and liaising 
between different HCV care pathways or delegated HCV staff. 
Harm reduction Harm Reduction is an evidence-based, person-centred approach that 
seeks to reduce the health and social harms associated drug use without 
requiring people stop using drugs.   
Staff responsible for any 
part of HCV testing 
and/or treatment 
This refers to all staff who have been upskilled or trained to deliver any 
part of HCV testing and/or treatment to service users.   
Behavioural contract The behavioural contract, or verbal agreement, is an established 
behavior change technique based on positive reinforcement. In the 
context of services providing HCV testing and treatment to populations 
at an increased risk of HCV, this could take the form of discussing 
treatment engagement between service user and service provider, or 
collaboratively planning on how, where and when the service user will 
take required HCV medication.  
Standard Operating 
Procedures 
Standard Operating Procedures (SOPs) are detailed written instructions 
to achieve uniformity and consistency of the performance of a specific 










Evidence-based and theoretically-informed recommendations 





Hepatitis C Virus (HCV) is a blood-borne virus that can seriously damage the liver and is spread mainly 
through blood-to-blood contact with an infected person. Despite effective prevention interventions 
such as Opioid Substitution Treatment, chronic HCV prevalence remains at around 40% among people 
who inject drugs (PWID) in the UK. New direct acting anti-viral therapies (DAA) are oral treatments 
that are safe, have little to no side effects, shorter treatment duration (8-12 weeks) and are highly 
effective (>90%) if adherence is adequate. Scaling-up HCV case-finding and treatment in the 
community in services in contact with PWID is critical to UK ambitions to contribute to the World 
Health Organization (WHO) ambition to eliminate HCV as a public health threat by 2030 (Harris, 
Edmundson, Costella et al, 2020). The WHO elimination target is to reduce the incidence of chronic 
HCV infection by 80% and HCV mortality by 65% by 2030.  To date these biomedical developments 
have not been matched by equivalent developments concerning how best to design and deliver 
services. This guide provides evidence and practical advice and recommendations towards addressing 
this key gap.  
 
Evidence from theoretical mathematical modelling suggests that eliminating HCV (i.e. reducing new 
cases of HCV to zero) requires a strategic combination of harm reduction programmes (e.g. needle 
exchange, methadone maintenance programmes or supervised injecting facilities) combined with HCV 
treatment. In order to deliver these population-level effects, it is vital that every opportunity is taken 
to test and treat. This demands implementing HCV testing and treatment pathways at scale in multiple 
settings, ideally simultaneously, to maximise population reach and radically reduce population-level 
viremia and incidence.  
 
In order to investigate, and subsequently share, key lessons learned about implementing HCV testing 
and treatment at scale, we conducted a detailed retrospective qualitative investigation of the 
experiences of implementing diverse testing and treatment pathways across a range of key settings 
in one key UK area (NHS Tayside). These comprised four community based settings: enhanced needle 
and syringe programmes (ENSP), pharmacies, specialist drug treatment clinics and prison. We did not 
investigate any testing and treatment pathways in a hospital or General Practitioner setting. NHS 
Tayside was chosen as a case site because of its position within the UK as a major innovator in relation 
to HCV care. Critically, the analyses underpinning the current guide apply beyond Tayside. By using 
key tools and frameworks from behavioural and implementation science, we have systematically 





• To inform decision-making concerning the implementation of community and in-prison HCV 
testing and treatment pathways across local and national contexts. 
 
• To inform decision-making concerning the implementation of HCV testing and treatment 
pathways in specific settings namely, enhanced needle and syringe programmes (ENSP), 
pharmacies, drug treatment clinics in community, and prison. 
 





Intended audience for the guide  
 
This guide is primarily intended for clinical leads, health practitioners, NGOs, third-sector agencies, 
community and patient groups, senior policy-makers and commissioners who are responsible for 
scaling up HCV testing and treatment in their local or national context for those who are at risk of 
infection through injecting drug use. In particular, we provide recommendations for the following 
community based settings: Enhanced needle and syringe programmes, pharmacies, drug treatment 
clinics in community, and prisons. 
 
How to use the guide  
 
This guide has been written as a resource to support the process of implementing HCV testing and 
treatment at scale. It is likely to be highly relevant across the UK and relevant to other OECD countries. 
 
The guide is structured around presenting a series of recommendations. Firstly, we present 
recommendations that relate to all the HCV treatment pathways. These are structured along the WHO 
key areas of delivering HCV testing and treatment (WHO, 2016); these are: 1. Access, 2. HCV Testing, 
3. HCV Treatment, and 4. Support during and after HCV treatment. Secondly, we present 
recommendations that are pathway-specific and relate more closely, but not entirely, to what we have 
learned from pathway-specific insights.  
 
Each recommendation is numbered and presented in bold. For the interested reader, we collated all 
recommendations accompanied by a brief rationale based on (a) existing published evidence, (b) 
analysis of data collected in Tayside from service providers, peer workers and service recipients and 
(c) feedback from expert stakeholders including service users (recruited from Tayside and wider 
Scotland) in appendix 1. In appendix 2, we explain our approach and method to data collection, 
analysis, coding and translation into recommendations. 
 
The recommendations involve three staff groups in the HCV treatment settings (see Figure 1). We 
referred to specific service providers in the recommendations using these descriptors, i.e. a) all 
providers, b) those responsible for any part of HCV testing and/or treatment and c) HCV nurse 





























A brief summary of where the recommendations come from  
 
The guide is developed from three complementary analytic phases.   
 
Phase 1: We interviewed 40 service providers including peer workers, and 31 service users across NHS 
Tayside. Using deductive thematic analysis, we identified the barriers and facilitators to key steps in 
each HCV treatment setting, i.e. we mapped out who did what to whom, when, where and in what 
sequence, and we considered what worked and what did not work at each of these key steps (see 
figure 2). This gave us detailed insights into what happened within Tayside across and within each HCV 
care setting. In this way the guide is evidence-based. Interested readers are invited to see this analysis 
and the key steps across all HCV treatment settings including indicative quotes describing key barriers 
and facilitators in upcoming peer-reviewed publications.  
 
Phase 2: To overcome the context-specific nature of our Tayside data we drew upon decades of 
behavioural and implementation science research to theorise our findings and identify a more 
generalisable way of understanding the Tayside experience. We coded each distinct barrier and 
facilitator, to each key step of each care pathway, with the Theoretical Domains Framework (Atkins et 
al, 2017). This enabled us to theorise the causal mechanisms that were important for implementing 
specific steps within the specific care pathways.    
 
Phase 3.  To make future facing recommendations for other regions considering the implementation 
of HCV care pathways, we used the Behaviour Change Wheel (Michie, van Stralen & West, 2011). 
Again, this approach draws on decades of previous research and enables the precise specification of 
intervention functions, and behaviour change techniques that match the theorised causal mechanism 
identified in phase 2. In this way we were able to specify precise and detailed recommendations 
shared across all treatment settings as well as specific to some settings. The use of this approach 





enables a granular, highly specific means to generate evidence-based and theoretically informed 
recommendations.  
 
Phase 4. To validate our recommendations, we sense-checked the recommendations for each setting, 
and those across all settings, via stakeholder events in Tayside, and across Scotland. Stakeholders 
included service providers from the third sector (including peer workers), the NHS, pharmacies at 
frontline, clinical lead, manager and commissioner level, and service users. All stakeholders were 
asked to apply the APEASE criteria (Affordability, Practicability, Effectiveness, Acceptability, Side 
effects and Safety, and Equity) to recommendations (Michie, Atkins & West, 2014). In this way, we co-
produced pathway recommendations to ensure applicability and implementability to context-specific 
settings and pathways. We also engaged with previous research evidence to cross-reference our 
recommendations. 
 
Figure 2 shows the key steps in the HCV treatment pathway that were common to all treatment 
settings. This pathway is an idealised journey through HCV testing and treatment, and should be 
considered as flexible and adaptable to local resources and needs. For example, where Point of Care 
testing and qualified healthcare staff are available, several key steps (e.g. testing, medical history 
taking, notification of test result and setting up of treatment plan can happen during one visit). 
 
Our recommendations provide detail and guidance concerning how to implement the key steps within 
and across diverse settings. It is worth highlighting that implementing HCV testing and treatment 
across multiple settings is highly likely to have reinforcing effects across the whole health care system 














































































[Visit 1] Access 
Service user attends setting offering HCV testing and 
treatment 
[Visit 1] HCV Testing  
Staff approach service user, initiate HCV conversation, 
promote HCV testing and treatment as part of a wider 
harm reduction strategy (e.g. vein care, naloxone and 
overdose prevention, BBV testing) and conducts HCV 
test (e.g. DBST for HCV antibodies and HCV PCR). 
 
[Visit 3] HCV Treatment and ongoing support 
Service user is notified of HCV test result (as per 
preference). If HCV PCR test is positive, set up 
prescription plan according to service user’s preference. 
DAA collection at preferred pharmacy. 
 
Ongoing support. Service user collects DAA prescription 
from pharmacy. All staff involved in service user’s HCV 
treatment liaise to ensure ongoing engagement and 
completion of HCV treatment. 
 
If HCV PCR and liver 
assessment values are 
outwith the norm, refer 
service user for further 
testing to specialist (e.g. 
at hospital). The service 
user re-joins the pathway 
when assessed as safe to 
do so. 
 
[Visit 2] HCV Testing  
Service user is referred to 
HCV nurse specialist or 
qualified healthcare 
professional for bloods 
assessment, medical history 
and venepuncture (if 
required: HCV PCR). 
Ongoing support. Service user is invited for annual HCV review and repeat HCV testing post SVR 
when they visit a setting that offers HCV testing and treatment via diverse means (e.g. formally 
and opportunistic). 
 
[Visit 4] SVR test and Ongoing support. 
Service user attends HCV setting of choice for SVR12 
test. 
Service user is notified of SVR12 result (as per 
preference). 
Legend 
- - - - - Adjust according to service’s 
resources and individual service user. 
 





Structure of the guide   
 
The guide is organised into the following sections:  
 
Section 1 Recommendations for all settings (i.e. services dealing with people at an increased risk of 
HCV when scaling up HCV testing and treatment)  
It is imperative that this section is read and understood in conjunction with the individual pathway 
recommendations. It contains all the shared recommendations that apply to each and every setting. 
Sections 2-5 can be read in any order.  
 
Section 2. Key recommendations ENSP services 
This section describes key recommendations for optimal implementation of HCV testing and 
treatment in ENSP settings.  
 
Section 3. Key recommendations Pharmacies 
This section describes key recommendations for optimal implementation of HCV testing and 
treatment in pharmacies who offer opiate substitution therapy. 
 
Section 4. Key recommendations community Drug treatment clinics 
This section describes key recommendations for optimal implementation of HCV testing and 
treatment for drug treatment clinics.  
 
Section 5. Key recommendations Prisons 
This section discusses the key recommendations for optimal implementation of HCV testing and 
treatment in prisons.  
 
Appendix 1. Recommendations with Rationales 
This section lists all recommendations with a supporting rationale, utilising evidence from the 
literature (where available), our research findings from NHS Tayside and feedback from experts at our 
stakeholder events in Tayside and across Scotland. 
 
Appendix 2. Methods 
This section provides a detailed summary of the qualitative research methods used to generate the 
recommendations listed in this implementation guide. 
 
Appendix 3. Example/ Template 
This section contains an example or template of a standard operating procedure or guideline on 
supporting the implementation of HCV testing into patient pathways. 
 
Appendix 4. Acknowledgements 
This section acknowledges the contribution, input and feedback from various stakeholders into the 














Section 1:  Recommendations for all settings (i.e. services dealing with people 
at an increased risk of HCV) when scaling up HCV testing and treatment  
 
 
Recommendations relevant to all services where HCV testing and treatment may be offered. These 





Recommendation 1.1: Implement a nurse-led community service model in HCV testing and 
treatment. This facilitates the coordination of HCV testing and treatment across community settings, 
while providing active support for services users requiring more specialist care, e.g. liver assessment 
and harm reduction services.  
 
 
Recommendation 1.2: Establish and maintain a non-judgemental, non-stigmatising, open and 
inclusive positive service culture through good management, annual appraisals and regular reflective 
practice. Consider the selective recruitment and retention of key staff. Integrate cultural aspects 
regarding working with people at an increased risk of HCV into staff supervision and consider 
addressing these in your organisational values and mission statement. New staff (including peer 
workers) should have specific and dedicated training on these aspects and should shadow existing 
staff where possible. 
 
 
Recommendation 1.3: It is imperative to recruit peer workers, with lived experience of substance 
misuse, recovery and – if possible – HCV treatment to facilitate service users’ engagement with HCV 
testing and treatment. Peer workers are core to initiating contact (including outreach), maintaining 
engagement with service users, and developing a positive organisational culture. Support this through 
training, regular supervision, appraisals and continuous professional development.   Consider 
upskilling ex-service users, with local knowledge of the drug culture, from initially unpaid volunteers 
to paid staff (without impacting on peer workers’ welfare benefit income). 
 
 
Recommendation 1.4: Depending on local resources, consider co-locating the HCV treatment setting 
(i.e. needle and syringe, drug treatment, pharmacy, prison) with a HCV nurse specialist or other 
qualified HCV health care provider, if possible in the same building or within proximity. This needs 
to be facilitated by clear communication lines that support signposting and collaborative care across 
co-located services to enable HCV testing and treatment.  
 
 
Recommendation 1.5: Provide education for all staff on the benefits and value of HCV testing and 
treatment to the NHS, the local setting and the individual service user. Ensure that all staff are aware 
of the long term consequences of undiagnosed and untreated HCV, and are able to signpost service 
users to HCV service providers. This can be achieved by providing a succinct online awareness training 
package, as part of staff’s ongoing Continuing Professional Development (CPD).  The aim is to facilitate 
engagement with HCV and wider BBV testing and treatment among service users, but also among 
service providers in the setting and elsewhere relevant, e.g. the third sector, Prison services, the Police 
Force. 
 






Recommendation 1.6: In addition to recommendation 1.5, enhance education for all staff (i.e. in 
direct contact with service users) on service users’ experience and fear of stigma, including self-
stigmatisation, of HCV in diverse treatment settings. This can be achieved by providing a succinct 
online awareness training package, as part of staff’s ongoing CPD. The aim is to facilitate ownership in 
addressing stigma associated with HCV, and to understand variations of stigma, e.g. anticipated or 
feared stigma vs actual experienced stigma vs self-stigmatisation.   
 
 
Recommendation 1.7: Implement a drop-in service model to provide opportunistic HCV testing and 
treatment in line with the availability and the needs of service users.  Where co-located with other 
services, this needs to be achieved by restructuring the provision of services to maximise service users’ 
visits via simultaneous opening hours of clinics and by training staff who can effectively role-share to 
reduce service users’ waiting times.   
 
 
Recommendation 1.8: In addition to recommendation 1.7, utilise a diverse range of (assertive) 
outreach or homecare arrangements to enable access and facilitate HCV testing and treatment. For 
example, consider digital or telephone HCV consultations, home visits and mobile van(s) offering HCV 
testing and treatment delivery. This (together with peer work) may be particularly valuable in the 
promotion of HCV testing and treatment, facilitating continuity of HCV care and ongoing harm 
reduction for service users who are unable to attend other community based pathways and also those 
who have yet to come into contact with services. 
 
 
Recommendation 1.9: For all services, ensure commissioning processes detail service level 
agreements including standard operating procedures (SOPs) or guidelines that facilitate HCV testing 






Recommendation 1.10: Implement a multiple testing strategy (HCV, HBV, HIV) as part of a wider 
harm reduction package. Delivering HCV testing to service users in settings where they also have 
access to other BBV testing and treatment (HIV and HBV) is likely to be an effective way to improve 
wider BBV testing uptake. This can be achieved by training up all staff responsible for any part in HCV 
testing (DBST and venepuncture) to maximise opportunities for testing (including via peer outreach). 
If HCV testing is offered as part of a wider BBV testing strategy, then ensure staff are able to inform 
and discuss all test results, and are trained up to understand the sensitivities of informing on a positive 
diagnosis (e.g. HIV) (see recommendation 1.18). 
 
Recommendation 1.11: Minimise the steps in the HCV treatment pathway via the co-ordination of 
key tasks. For example, consider initiating the HCV testing conversation with the aim of conducting 
HCV testing immediately. Depending on local resources and flexibility with the individual service user, 
consider requesting two dry blood spot tests during the first visit to assess for a) HCV antibodies (as 
part of a BBV testing package), and b) HCV PCR. If venepuncture is deemed essential, arrange an 
additional visit for the service user to the HCV nurse specialist or other qualified healthcare 
professional. 
 






Recommendation 1.12: In addition to recommendation 1.11, consider offering (postal) HCV self-
testing kits (e.g. dry blood spot tests) to service users. By offering a choice to the service user, and 
handing over autonomy, engagement with HCV testing and treatment may increase, especially for 
those service users who are unable to attend outreach clinics. Consider utilising designs (format, 
written and pictorial instructions) of existing effective self-testing kits (e.g. sexual health).  Caution is 
required as there are currently no peer-reviewed published studies on the feasibility, acceptability 
and efficiency of HCV self-testing kits among people who inject drugs. 
 
 
Recommendation 1.13: [refer to visit 1] When convenience and speed of HCV testing and treatment 
are vital, consider implementing point of care (POC) testing to enable rapid HCV PCR testing, result 
notification and treatment initiation, particularly for high risk service user populations. This means 
that HCV testing and diagnosis could be delivered on the same day, thereby enabling timely HCV 
treatment. While some training is required to operate, maintain and utilize outputs from relevant POC 
test machines (such as GeneXpert), this does not necessarily require specialist qualifications.   
 
 
Recommendation 1.14: Depending on local agreements and resources, ensure that staff responsible 
for any part of HCV testing and/or treatment in each setting are able to role-share to ensure timely 
and consistent HCV testing and treatment. Where possible, consider utilising local knowledge and 
involve existing services where people who inject drugs attend or reside, for example probation, social 
work, third sector organisation, homeless hostels and health services. Consider the impact of 
individual relationships between staff and service users, and assign those staff with existing 
relationships to initiate the HCV conversation, promote HCV testing and treatment and support the 
service user to ensure HCV engagement. [Refer to recommendations 1.26 and 1.27 with regards to 




Recommendation 1.15: [refer to visit 1] Ensure staff responsible for any part of HCV testing and/or 
treatment are able to initiate and conduct an HCV testing conversation at every opportunity. This 
can be achieved through a package of training, appraisal, CPD and refresher training. Ensure that all 
staff responsible for any part of HCV testing and/or treatment are aware of the value of and 
consequences of not doing HCV testing within the service. The content of training should include 
working with experienced staff to co-produce examples of good and poor timing of initiating the HCV 
conversation, and good and poor examples of a tailored, normalised HCV conversations.  
 
 
Recommendation 1.16: [refer to visit 1] Ensure staff responsible for any part of HCV testing and/or 
treatment are able to conduct dry blood spot tests (DBST) or alternative biosampling HCV tests 
through a package of hands-on practical training, opportunities to practice, appraisals and regular 
refresher training. Ensure all staff responsible for any part of HCV testing and/or treatment 
understand their role in doing DBSTs (or alternative HCV test), and provide opportunities to 
interdisciplinary groups where good techniques are modelled across roles. 
 
 
Recommendation 1.17: [refer to visit 1] Ensure staff responsible for any part of HCV testing and/or 
treatment respect the service user’s preferences in communicating with the HCV nurse specialist or 
any member of staff working in the HCV service. This needs to be facilitated by all staff responsible 





for any part of HCV testing and/or treatment providing support to the service user in the decision 
making process of how (e.g. in a letter, over the phone) and by whom they would like to be notified 
of their HCV test results (i.e. potential positive HCV diagnosis). Ensure that service users are aware 
that all staff responsible for any part of HCV testing and/or treatment and the HCV nurse specialists 
are colleagues in a multi-disciplinary team.  
 
 
Recommendation 1.18: [refer to visit 2] Ensure staff responsible for any part of HCV testing and/or 
treatment are able to inform and discuss any HCV test results (both, HCV antibodies and HCV PCR) 
through a package of dedicated training, appraisals and ongoing CPD. All staff responsible for any 
part of HCV testing and/or treatment should be encouraged to reflect on their skills in normalising 
HCV test results, including aspects of regular HCV testing, the importance of harm reduction and – 
where appropriate – the need for further HCV testing and/or HCV treatment. The content of training 
should be based on working with experienced HCV specialist nurses (or other qualified health 
professional) to co-produce examples of good and poor conversations about any HCV test result, in 
relation to emotional and social consequences.  
 
 
Recommendation 1.19 [refer to visit 2] Ensure staff responsible for any part of HCV testing and/or 
treatment prioritise referral of the service user to the HCV nurse specialist or other qualified health 
care professional if further HCV PCR testing or HCV assessment via venepuncture is required. This 
needs to be achieved via training (e.g. brief intervention) to optimise the service user’s engagement 
with further HCV testing. Training should include co-producing successful approaches and ‘good’ 
conversations helping the service user to prioritise attending the HCV clinic or other qualified health 
care professional, i.e. staff need to reassure the service user, normalise the HCV test result and 
emphasise the urgency of further HCV blood tests.  
 
 
Recommendation 1.20: [refer to visit 2] In order to maximise all opportunities to obtain required 
blood samples, train other qualified health care professional (such as community-based 
practitioners) to initiate the conversation about finding suitable veins and then to conduct 
venepuncture on the service user for the HCV PCR blood test. This needs to be achieved by providing 
a comprehensive and hands-on training package to other qualified health care staff and new HCV 
nurse specialists, including peer-led learning on the sensitivities when drawing bloods from people 
who inject drugs. Consider specific online learning materials, fact sheets or visual illustrations 
regarding the ‘best’ and alternative sites on the body to draw bloods from in people who inject drugs.  
 
 
Recommendation 1.21: Promote the benefits of HCV testing and treatment to service users. This 
could include the provision of posters, leaflets, short films, social media posts and visual materials 
providing personal testimonies of service users who completed the HCV treatment. Consider providing 
information on the number of service users successfully tested and treated locally or regionally to 
encourage uptake of HCV testing and treatment. The aim is to normalise HCV testing and treatment, 















Recommendation 1.22: [refer to visit 3] Provide training on core aspects and the sequence of core 
aspects in setting up the HCV treatment plan for (new) HCV nurse specialists or other qualified 
health care professional. This can be achieved by co-producing successful treatment plan 
conversations via peer learning and ongoing CPD. As part of the treatment plan conversation, enhance 
HCV nurse specialists’ skills of motivational interviewing to promote the treatment and its benefits. 
This is to facilitate the service user’s engagement.  
 
 
Support during and after HCV treatment 
 
Recommendation 1.23: [refer to visit 3] Co-produce verbal agreements (e.g. behavioural contracts) 
with service users to assist adherence to HCV treatment, depending on the relationship between 
service provider and service user. This should be achieved by providing a training package aimed at 
developing agreements and behavioural contracts between staff responsible for any part of HCV 
testing and/or treatment and service users. For example, scripts of ‘good’ behavioural contract 
conversations could be included, informed by experienced HCV nurse specialists or other key staff 
(e.g. pharmacists) who use behavioural contracts as part of concurrent OST treatment. The aim is to 
facilitate engagement, HCV treatment completion and therapeutic collaboration in a culturally 
sensitive and constructive manner. 
 
 
Recommendation 1.24: [refer to visit 3] Train staff responsible for any part of HCV testing and/or 
treatment to motivate, support and review the service user during HCV treatment to facilitate 
treatment adherence. Staff training can be achieved by co-producing ‘good’ review and support 
conversations with experienced staff or HCV nurse specialists, and may be particularly relevant for 
HCV services that do not routinely offer new interventions. These conversations should include 
aspects of brief interventions such as motivational interviewing, and verbal reinforcements for the 
service user’s continued adherence to the HCV treatment plan.  
 
 
Recommendation 1.25: [refer to visit 4] View SVR12 testing as an opportunity to promote harm 
reduction services and thereafter adopt a proactive approach to regular follow-up testing and 
continuous harm reduction support. This needs to be achieved via training of all staff responsible for 
any aspect of HCV testing or treatment to be flexible and opportunistic in their approach to obtaining 
DBSTs (or alternative biosampling HCV test) post HCV treatment, and thereafter as part of ongoing 
harm reduction and recovery. This should include training and assessment of cultural and clinical 
competencies to maintain and utilise the therapeutic relationship with the aim of normalising harm 




Recommendation 1.26: Implement an HCV Testing and treatment administrative data system. This 
could be achieved through a live HCV database to record service users with an antibody test, and to 
track those with chronic HCV infection (e.g. all HCV PCR positives). This database can further be used 
to facilitate routine audits of HCV testing and treatment as part of caseload management and care 
planning. In addition, consider nominating a ‘HCV facilitator’ or ‘HCV champion’ in each treatment 
setting as the main liaison contact between HCV nurse specialists and staff, as well as facilitating 
effective HCV case management and monitoring. This needs to be supported by agreeing on national/ 









Recommendation 1.27: In addition to recommendations 1.25 and 1.26, ensure a responsive system 
is in place to share information across HCV services and patient pathways, for example when a 
service user disengages from any HCV service. Clearly define the processes and procedures involved 
in HCV care transition when a service user diverts from the HCV service, or chooses to disengage from 
the HCV nurse specialist or other qualified health professional. This can be facilitated through national 
data sharing agreements across NHS and non-NHS service providers who are involved in the patient 
pathway for the purpose of HCV testing and treatment. Maintain awareness of these protocols 













































Section 2:  Recommendations for Enhanced Needle Syringe Programme 
delivering testing and treatment for HCV 
 
 
Key Recommendations for the successful implementation of HCV testing and treatment in Enhanced 
Needle Syringe Programme (ENSP) services.  
 
These complement the recommendations already outlined in Section 1 ‘Shared Recommendations 
(pp. 14-19)’ and are additional setting-specific recommendations. 
 
 
Recommendation 2.1: Implement an enhanced needle and syringe programme service as part of a 
community ‘hub’ model to providing and promoting HCV testing and treatment, and harm 
reduction. This can be achieved by establishing a network of community services and multi-
disciplinary agency workers (e.g. comprising NHS and third sector such as harm reduction and social 
services) to co-ordinate care, treatment and recovery, to involve peer workers as part of the service 
and to enable co-location of services to maximise reaching service users.  
 
 
Recommendation 2.2: Establish and share a range of successful communication methods with the 
service user that facilitate follow up for HCV tests, results, and HCV treatment, especially to promote 
regular HCV testing post treatment to detect reinfections early for further HCV treatment. 




Recommendation 2.3: Ensure flexibility in the delivery of the ENSP service model of HCV care by 
upskilling staff responsible for any part of HCV testing and/or treatment to engage in an outreach 






























Key Recommendations for the successful implementation of HCV testing and treatment in 
Pharmacies 
 
These complement the recommendations already outlined in Section 1 ‘Shared Recommendations 
(pp. 14-19)’ and are additional setting-specific recommendations. 
 
 
Recommendation 3.1:  Ensure processes such as contractual frameworks, quality standards and 
financial processes for the implementation of HCV testing and treatment are in place in pharmacies. 
This needs to be achieved through the use of established procurement systems. 
 
 
Recommendation 3.2: Enhance training packages on interpersonal skills to include aspects of active 
listening, rapport building and cultural competence for staff responsible for any part of HCV testing 
and/or treatment. Staff should be skilled to move between a commercially based relationship 
(customer and supplier) to one that effectively promotes culturally sensitive and wider holistic 
approaches to health and wellbeing including HCV care provision. 
 
 
Recommendation 3.3: Train and upskill a sufficient number of pharmacy staff to deliver both, HCV 
testing (DBST) and treatment. This can be achieved via two models, dependent on local preference: 
either train up all staff to be able to conduct HCV testing (DBST) and HCV treatment, or at a minimum 
train a small group of key staff who are primarily responsible for conducting HCV testing and treatment 
(including HCV prescribing). Liaise with HCV nurse specialist or other qualified healthcare professional 
if specialist skills for venepuncture are required. Training should include regular appraisals of 
competencies and consistency in the delivery of HCV testing and treatment. 
 
 
Recommendation 3.4: Enhance staff training to include behaviour change competencies to facilitate 
the service user’s HCV treatment completion for staff responsible for any part of HCV testing and/or 
treatment. Training packages should include issues such as using behavioural contracts with service 
users (e.g. requesting a verbal commitment to treatment completion) because most service users 
collect their HCV prescriptions from pharmacies, and are therefore in regular contact with pharmacy 
staff. For example, training scripts of effective conversations could be included, informed by prior 
experience of HCV nurse specialists or pharmacy staff. The aim is to facilitate engagement, HCV 
treatment completion and therapeutic collaboration in a culturally sensitive and constructive manner. 
 
 
Recommendation 3.5: To maximise the uptake of HCV testing and treatment, HCV nurse specialists 
should develop and share an accessible list of potential HCV service users who receive opiate 
substitution therapy. This needs to be achieved by pharmacies collaborating closely with the HCV 










Section 4:  Recommendations for community Drug Treatment Teams 
delivering testing and treatment for HCV 
 
 
Key Recommendations for the successful implementation of HCV testing and treatment in Drug 
Treatment 
 
These complement the recommendations already outlined in Section 1 ‘Shared Recommendations 
(pp. 14-19)’ and are additional setting-specific recommendations. 
 
 
Recommendation 4.1: Implement a standardised opt-out HCV testing model in all community drug 
treatment services. Support drug treatment staff to prioritise the promotion of HCV testing and 
treatment to the service user. This needs to be achieved by enabling drug treatment staff to provide 
person-centred care while helping the service user to (re-) prioritise HCV engagement among 
competing needs.  
 
 
Recommendation 4.2: Co-ordinate drug treatment and the HCV care pathway to facilitate service 
user engagement, timely HCV testing and treatment and regular contact via shared outreach 
appointments and home visits. This includes physically collecting service users for their HCV 
appointments, utilising digital technologies as part of HCV consultations, as well as providing HCV 
testing and treatment within the service user’s home. This needs to be achieved by formally setting 






























Section 5:  Recommendations for staff working in prisons delivering testing 
and treatment for HCV 
 
 
Key Recommendations for the successful implementation of HCV testing and treatment in Prisons 
 
These complement the recommendations already outlined in Section 1 ‘Shared Recommendations 
(pp. 14-19)’ and are additional setting-specific recommendations. 
 
 
Recommendation 5.1: Implement a standardised opt-out HCV testing model in all prison services. 
As a routine part of admission procedures and processes to prison, offer BBV testing (including HCV 
testing) to all individuals entering custody regardless of their legal status (i.e. remand, sentenced or 
those awaiting sentencing).  Support prison staff at admission to promote and prioritise HCV testing 
as part of the admission procedure. 
 
 
Recommendation 5.2: Ensure effective and formalised protocols are in place for sharing clinical 
information among those staff responsible for any part of HCV testing and/or treatment inside 
prison, between prisons, between the prison and specialist HCV services. This is to ensure HCV 
continuity of care for service users including those transferring between prisons and transitioning to 
the community.  
 
 
Recommendation 5.3: Promote HCV testing and treatment via a dedicated prison-based healthcare 
facilitator. This needs to be an individual with excellent interpersonal skills to establish relationships, 
and with privileged access to residential officers, (eligible) service users in prison and delegated 
healthcare and HCV staff. For example, this could be a health care worker or a residential officer.  
Consider recruiting more than one healthcare facilitator to cover potential staff absence. Provide 
essential training to the health facilitator(s) on HCV engagement, HCV testing and treatment.  
 
 
Recommendation 5.4: Ensure all HCV testing methods are available including oral swabs, which 
could be utilised in private areas in the residential prison halls. Oral swabs are less expensive, almost 
as accurate as DBST and more convenient to conduct for both, service users and those staff that use 
oral swabs. While oral swabs can only be used to test for the presence of HCV antibodies, they are 
suitable with HCV low risk populations and when testing occurs outside clinic environments such as in 
residential prison halls. This needs to be achieved by restructuring HCV service provision to maximise 
contact at times when people residing in prison are available.  
 
 
Recommendation 5.5: In addition to recommendation 5.2, provide training on how to preserve 
confidentiality when communicating with people residing in prison about HCV and thus avoiding 
possible stigmatisation. Consider liaising with the service user via the HCV facilitator, peer workers, 
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Appendix 1 Recommendations with Rationale 
 
Recommendation Rationale 
1.1 Implement a nurse-led community service model in HCV testing and 
treatment. This facilitates the coordination of HCV testing and treatment 
across community settings, while providing active support for services 





Decentralised HCV testing and treatment have been proved to be more cost-
effective than HCV consultant, HCV nurse specialist or primary practitioner (GP) 
only models (e.g. Ramachandran et al, 2020). Our analysis from NHS Tayside 
suggests that HCV nurse-led community services are powerful and successful in 
providing patient-centred HCV care. Experts in our stakeholder groups 
emphasised the value and benefits of decentralising HCV testing and treatment 
led by HCV nurse specialists in outreach pathways (i.e. needle and syringe 
programmes, drug treatment, pharmacy and prison). 
1.2 Establish and maintain a non-judgemental, non-stigmatising, open and 
inclusive positive service culture through good management, annual 
appraisals and regular reflective practice. Consider the selective 
recruitment and retention of key staff. Integrate cultural aspects regarding 
working with people at an increased risk of HCV into staff supervision and 
consider addressing these in your organisational values and mission 
statement. New staff (including peer workers) should have specific and 
dedicated training on these aspects and should shadow existing staff 
where possible. 
The experience of stigma, or the fear of stigma from health care professionals is 
a known commonly reported barrier to engaging with HCV services by people 
who inject drugs (Treloar et al, 2013; Madden et al, 2018). Our analysis from 
NHS Tayside indicates that service users prefer and attend those services where 
they do not feel judged, and/or have established long lasting trusting 
relationships with service providers. Experts in our stakeholder events also 
reinforced the importance and impact of mindfully establishing and maintaining 
a safe, non-judgemental and stigma-free organisational culture to facilitate HCV 
testing and treatment. 
1.3 It is imperative to recruit peer workers, with lived experience of 
substance misuse, recovery and – if possible – HCV treatment to 
facilitate service users’ engagement with HCV testing and treatment. 
Peer workers are core to initiating contact (including outreach), 
maintaining engagement with service users, and developing a positive 
organisational culture. Support this through training, regular supervision, 
appraisals and continuous professional development.   Consider upskilling 
ex-service users, with local knowledge of the drug culture, from initially 
unpaid volunteers to paid staff (without impacting on peer workers’ 
welfare benefit income). 
The recruitment of peer workers as volunteers, and subsequently employees 
facilitates HCV testing and treatment because service users tend to engage 
particularly well and fully with peers (e.g. Ashford et al, 2018). Evidence from 
NHS Tayside, in particular in enhanced needle and syringe programmes, 
highlights the benefits of including peer workers as part of the HCV service 
model. Experts in our stakeholder group confirmed the importance of peer 
workers in enhanced needle and syringe programmes, and strongly endorsed 
recruiting peer workers in community drug treatment and in prison, with 
employment and range of responsibilities depending on the relevant pathway. 
1.4 Depending on local resources, consider co-locating the HCV treatment 
setting (i.e. needle and syringe, drug treatment, pharmacy, prison) with 
a HCV nurse specialist or other qualified HCV health care provider, if 
The co-location of harm reduction, recovery and HCV services in a ‘one-stop 
shop’ (WHO, 2012) maximises on all opportunities to engage a service user 
attending a HCV service. Our analysis from NHS Tayside demonstrates that 





possible in the same building or within proximity. This needs to be 
facilitated by clear communication lines that support signposting and 
collaborative care across co-located services to enable HCV testing and 
treatment. 
 
merging HCV nurse specialists into the work spaces and environments where 
service users at risk of HCV attend creates a coherent, supportive and task-
sharing HCV service. Experts in our stakeholder group emphasised that co-
location of HCV services was essential in promoting and providing HCV testing 
and treatment to people who inject drugs. 
1.5 Provide education for all staff on the benefits and value of HCV testing 
and treatment to the NHS, the local setting and the individual service 
user. Ensure that all staff are aware of the long term consequences of 
undiagnosed and untreated HCV, and are able to signpost service users to 
HCV service providers. This can be achieved by providing a succinct online 
awareness training package, as part of staff’s ongoing Continuing 
Professional Development (CPD).  The aim is to facilitate engagement with 
HCV and wider BBV testing and treatment among service users, but also 
among service providers in the setting and elsewhere relevant, e.g. the 
third sector, Prison services, the Police Force.  
In order to effectively facilitate uptake of HCV testing and treatment, it is 
essential that all engagement opportunities with service users are utilised, and 
therefore all staff should have sufficient knowledge to promote and signpost 
service users towards HCV testing and treatment. Evidence from NHS Tayside 
suggests that service users are likely to engage with those staff they have 
existing relationships with first, and these staff may not necessarily be directly 
involved in HCV testing (e.g. social worker, or residential officer in prison 
settings). Experts at our stakeholder events emphasised the need for HCV and 
wider BBV education and awareness sessions delivered as part of mandatory 
staff training.   
1.6 In addition to recommendation 1.5, enhance education for all staff (i.e. in 
direct contact with service users) on service users’ experience and fear of 
stigma, including self-stigmatisation, of HCV in diverse treatment 
settings. This can be achieved by providing a succinct online awareness 
training package, as part of staff’s ongoing CPD. The aim is to facilitate 
ownership in addressing stigma associated with HCV, and to understand 
variations of stigma, e.g. anticipated or feared stigma vs actual 
experienced stigma vs self-stigmatisation.   
Anticipated and experienced stigma is a known barrier to engaging with HCV 
services among people who inject drugs. Evidence (service users) from NHS 
Tayside strongly suggests that some staff (for example, residential officers in 
prison) may be unaware of HCV stigma while service users experience a range 
of negative emotions (e.g. shame, guilt, disgust) which they feel unable to 
address out of fear of being stigmatised. Experts in our stakeholder groups 
stressed the importance of staff understanding stigma, and understanding how 
to alleviate this, e.g. by providing reassurance and establishing that the service 
user’s consent to all procedures is fundamental (i.e. giving control to the service 
user). 
1.7 Implement a drop-in service model to provide opportunistic HCV testing 
and treatment in line with the availability and the needs of service users.  
Where co-located with other services, this needs to be achieved by 
restructuring the provision of services to maximise service users’ visits via 
simultaneous opening hours of clinics and by training staff who can 
effectively role-share to reduce service users’ waiting times.   
Successful HCV testing and treatment among people who inject drugs is 
dependent on a flexible, opportunity-driven and culturally sensitive service 
model. Our analysis from NHS Tayside strongly suggests that a drop-in service 
model facilitates HCV testing and treatment to an otherwise under-served 
population. Experts in our stakeholder group supported the importance and 
value of a drop-in service when providing HCV testing and treatment. 





1.8 In addition to recommendation 1.7, utilise a diverse range of (assertive) 
outreach or homecare arrangements to enable access and facilitate HCV 
testing and treatment. For example, consider digital or telephone HCV 
consultations, home visits and mobile van(s) offering HCV testing and 
treatment delivery. This (together with peer work) may be particularly 
valuable in the promotion of HCV testing and treatment, facilitating 
continuity of HCV care and ongoing harm reduction for service users who 
are unable to attend other community based pathways and also those 
who have yet to come into contact with services. 
Maximising on opportunities to engage with service users beyond clinic 
environments or settings is a successful method to provide collaborative care. 
Our analysis from NHS Tayside indicates that assertive outreach, i.e. delivering 
HCV testing and treatment services to the patient at their location, allows HCV 
testing and referral for treatment in addition to (re)-establishing contact with 
those who have not contemplated or dropped out of HCV treatment. Experts at 
our stakeholder events summarised successful assertive outreach models, for 
example offering HCV treatment delivery to the home, or combining delivering 
needle and syringe equipment and conducting HCV testing during the same visit 
(subject to restrictions set out under Covid-19). 
1.9 For all services, ensure commissioning processes detail service level 
agreements including standard operating procedures (SOPs) or 
guidelines that facilitate HCV testing and treatment. All staff need to 
understand their roles and responsibilities within harm reduction 
approaches. 
The integration of HCV testing and treatment as part of core and routine work 
within each service supports consistent and ongoing harm reduction for people 
who inject drugs. Our evidence from NHS Tayside suggests that implementing 
clearly defined service level agreements, standard operating procedures (SOPs) 
or guidelines are valuable in helping staff to embed HCV services within their 
existing work roles. Experts in our stakeholder group supported setting up 
standard operating procedures or guidelines to ensure clarity and expectations 
of staff’s roles and responsibilities. [An example of such guidelines for HCV 
testing from NHS Tayside is available in Appendix 3]. 
1.10 Implement a multiple testing strategy (HCV, HBV, HIV) as part of a wider 
harm reduction package. Delivering HCV testing to service users in 
settings where they also have access to other BBV testing and treatment 
(HIV and HBV) is likely to be an effective way to improve wider BBV testing 
uptake. This can be achieved by training up all staff responsible for any 
part in HCV testing (DBST and venepuncture) to maximise opportunities 
for testing (including via peer outreach). If HCV testing is offered as part of 
a wider BBV testing strategy, then ensure staff are able to inform and 
discuss all test results, and are trained up to understand the sensitivities of 
informing on a positive diagnosis (e.g. HIV) (see recommendation 1.18). 
While HCV is the most prevalent blood borne virus infection among people who 
inject drugs, research evinces to maximise opportunities with service users to 
test for all BBVs (e.g. Solomon et al, 2020). Evidence from NHS Tayside clearly 
confirms the clinical value and benefit of providing a harm reduction service 
that includes HCV, HBV and HIV testing, thereby encouraging engagement with 
multiple treatments. Expert stakeholders strongly stressed the need, and the 
inherent duty of care, to provide HCV, HBV and HIV testing as part of a 
comprehensive harm reduction strategy. 
1.11 Minimise the steps in the HCV treatment pathway via the co-ordination 
of key tasks. For example, consider initiating the HCV testing conversation 
with the aim of conducting HCV testing immediately. Depending on local 
Maximising on a service user’s visit to a treatment pathway is a valuable and 
effective way of ensuring HCV care can be provided in focussed ‘HCV task 
clusters’ and may increase the uptake of treatment. Evidence from NHS Tayside 





resources and flexibility with the individual service user, consider 
requesting two dry blood spot tests during the first visit to assess for a) 
HCV antibodies (as part of a BBV testing package), and b) HCV PCR. If 
venepuncture is deemed essential, arrange an additional visit for the 
service user to the HCV nurse specialist or other qualified healthcare 
professional. 
suggests that HCV testing and treatment can be provided across as few as two 
or three visits or ‘meets’ with the service user (see figure 2), however flexibility 
to meet the service user’s needs and preferences is important to factor in. 
Experts in the stakeholder groups strongly emphasised that conducting as many 
HCV tasks as possible during a service user’s visit ensured that HCV care could 
be effectively and efficiently provided whilst increasing engagement in 
treatment. 
1.12 In addition to recommendation 1.11, consider offering (postal) HCV self-
testing kits (e.g. dry blood spot tests) to service users. By offering a 
choice to the service user, and handing over autonomy, engagement with 
HCV testing and treatment may increase, especially for those service users 
who are unable to attend outreach clinics. Consider utilising designs 
(format, written and pictorial instructions) of existing successful self-
testing kits (e.g. sexual health).  Caution is required as there are currently 
no peer-reviewed published studies on the feasibility, acceptability and 
efficiency of HCV self-testing kits among people who inject drugs. 
While the WHO is in the process of developing guidance on HCV self-testing 
(WHO, 2021), published evidence on the feasibility, acceptability and accuracy 
of HCV self-testing is limited and conflicting, in the UK (e.g. Guise et al, 2018) 
and elsewhere (e.g. Tonen-Wolyek et al, 2021; Reipold et al, 2021). Evidence 
from NHS Tayside is based on effective HCV testing and treatment within a 
supportive patient pathway that ensures access to healthcare staff. Experts in 
our stakeholder groups stressed the importance of flexibility and personal 
choice in HCV testing, and suggested that DBST self-testing should be an option 
as part of a future-facing intervention to widen access.   
1.13 [refer to visit 1] When convenience and speed of HCV testing and 
treatment are vital, consider implementing point of care (POC) testing to 
enable rapid HCV PCR testing, result notification and treatment 
initiation, particularly for high risk service user populations. This means 
that HCV testing and diagnosis could be delivered on the same day, 
thereby enabling timely HCV treatment. While some training is required to 
operate, maintain and utilize outputs from relevant POC test machines 
(such as GeneXpert), this does not necessarily require specialist 
qualifications.   
The speed of HCV test notification via POC testing can be vital in ensuring service 
user engagement, and can be successfully delivered by non-clinical frontline staff 
such as needle exchange workers (Noller & Bourke, 2020). Evidence from NHS 
Tayside (community and prison) confirms that HCV POC testing and result sharing 
help to expedite HCV treatment, and minimise HCV care visits with the 
healthcare professional to one visit only. Experts in our stakeholder groups 
highlighted the attractiveness, value and advantages of HCV POC testing but 
noted the financial costs associated with POC testing machines as a potential 
barrier for services and pathways. 
1.14 Depending on local agreements and resources, ensure that staff 
responsible for any part of HCV testing and/or treatment in each setting 
are able to role-share to ensure timely and consistent HCV testing and 
treatment. Where possible, consider utilising local knowledge and involve 
existing services where people who inject drugs attend or reside, for 
example probation, social work, third sector organisation, homeless hostels 
and health services. Consider the impact of individual relationships 
Local arrangements and knowledge of the settings where people who inject 
drugs attend, and utilizing existing relationships between staff and service users 
(Treloar, 2016) are vital to a flexible HCV testing approach ‘to reach the 
unreached’ (e.g. WHO, 2016). Evidence from NHS Tayside supports maximizing 
all opportunities to test and treat HCV through local relationships between HCV 
nurse specialists (NHS) and third sector organisations in Tayside, in addition to 
scaling up healthcare-facilitated community pathways (i.e. needle exchange, 





between staff and service users, and assign those staff with existing 
relationships to initiate the HCV conversation, promote HCV testing and 
treatment and support the service user to ensure HCV engagement. [Refer 
to recommendations 1.26 and 1.27 with regards to information sharing to 
facilitate HCV testing and treatment across settings (e.g. NHS and other 
agencies).] 
pharmacy, drug treatment and prison). Experts in our stakeholder groups 
emphasised the need for HCV testing to be highly flexible and delegate staff 
with ‘the best relationship’ to the individual service user in order to use any 
opportunity to test people who inject drugs and commence treatment. 
1.15 Ensure staff responsible for any part of HCV testing and/or treatment are 
able to initiate and conduct an HCV testing conversation at every 
opportunity. This can be achieved through a package of training, 
appraisal, CPD and refresher training. Ensure that all staff responsible for 
any part of HCV testing and/or treatment are aware of the value of and 
consequences of not doing HCV testing within the service. The content of 
training should include working with experienced staff to co-produce 
examples of good and poor timing of initiating the HCV conversation, and 
good and poor examples of a tailored, normalised HCV conversations. 
Upskilling staff to motivate service users with variable levels of readiness to 
change is a key output to successful HCV upscaling, and therefore timing, style 
and content of the initial HCV testing conversation are crucial. Evidence from 
NHS Tayside clearly demonstrates that staff benefit from guidance on careful 
timing and wording the initial HCV conversation, with the aim of promoting 
HCV testing and treatment to the service user. Experts in the stakeholder 
groups confirmed the importance of timing and the ability to effectively 
promote HCV testing and treatment to the service user, typically via Dry Blood 
Spot Tests ‘as the bread and butter’ of HCV testing methods. 
1.16 Ensure staff responsible for any part of HCV testing and/or treatment are 
able to conduct dry blood spot tests (DBST) or alternative biosampling 
HCV test through a package of hands-on practical training, opportunities 
to practice, appraisals and regular refresher training. Ensure all staff 
responsible for any part of HCV testing and/or treatment understand their 
role in doing DBSTs (or alternative HCV test), and provide opportunities to 
interdisciplinary groups where good techniques are modelled across roles. 
Successful upskilling of staff to conduct DBST (or alternative biosampling HCV 
test) is dependent on effectively demonstrating how to complete DBSTs on or 
with a service user. Evidence from NHS Tayside indicates that practical hands-
on DBST training is valuable and beneficial to both, experienced and 
inexperienced staff. Experts in the stakeholder groups affirmed that 
demonstrations of how to conduct a DBST are vital to successful HCV upscaling. 
1.17 Ensure staff responsible for any part of HCV testing and/or treatment 
respect the service user’s preferences in communicating with the HCV 
nurse specialist or any member of staff working in the HCV service. This 
needs to be facilitated by all staff responsible for any part of HCV testing 
and/or treatment providing support to the service user in the decision 
making process of how (e.g. in a letter, over the phone) and by whom they 
would like to be notified of their HCV test results (i.e. potential positive 
HCV diagnosis). Ensure that service users are aware that all staff 
responsible for any part of HCV testing and/or treatment and the HCV 
nurse specialists are colleagues in a multi-disciplinary team. 
In order to support and motivate the service user to commence HCV treatment, 
it is important to collaborate with the service user regarding who their 
preferred health care professional is for further communication. Evidence from 
NHS Tayside indicates that service users typically report highly negative 
emotions (e.g. self-shaming, feeling dirty, fear of stigma by health care 
professional) following disclosure of a positive HCV diagnosis, which could be 
mitigated if the messenger was a trusted, chosen staff. Experts at the 
stakeholder events insisted on the importance of enabling service users to 
make an informed choice regarding notification preference and contact person 
for a possible HCV diagnosis. 





1.18 Ensure staff responsible for any part of HCV testing and/or treatment are 
able to inform and discuss any HCV test results (both, HCV antibodies 
and HCV PCR) through a package of dedicated training, appraisals and 
ongoing CPD. All staff responsible for any part of HCV testing and/or 
treatment should be encouraged to reflect on their skills in normalising 
HCV test results, including aspects of regular HCV testing, the importance 
of harm reduction and – where appropriate – the need for further HCV 
testing and/or HCV treatment. The content of training should be based on 
working with experienced HCV specialist nurses (or other qualified health 
professional) to co-produce examples of good and poor conversations 
about any HCV test result, in relation to emotional and social 
consequences. 
It is essential that staff responsible for any part of HCV testing and/or treatment 
have the interpersonal skills to inform the service user of a HCV test result, 
especially if further HCV testing is required or the service user has a positive 
HCV diagnosis. Evidence from NHS Tayside strongly suggests that service users 
experience a wide range of negative emotions (e.g. guilt, shame, disgust, self-
hatred, fear, sadness) when realising that they are HCV positive. Experts in the 
stakeholder groups confirmed that disclosing both, HCV antibodies and HCV 
PCR results should be a routine part of staff’s professional responsibilities. 
1.19 Ensure staff responsible for any part of HCV testing and/or treatment 
prioritise referral of the service user to the HCV nurse specialist or other 
qualified health care professional if further HCV PCR testing or HCV 
assessment via venepuncture is required. This needs to be achieved via 
training (e.g. brief intervention) to optimise the service user’s engagement 
with further HCV testing. Training should include co-producing successful 
approaches and ‘good’ conversations helping the service user to prioritise 
attending the HCV clinic or other qualified health care professional, i.e. 
staff need to reassure the service user, normalise the HCV test result and 
emphasise the urgency of further HCV blood tests. 
Prompt further HCV testing is reliant on staff responsible for any part of HCV 
testing and/or treatment helping the service user to prioritise attending the 
HCV nurse specialist or other qualified health care professional for 
venepuncture (if applicable). Data from NHS Tayside indicates that service users 
may experience emotional upset, and benefit from prompt, often guided 
referrals to the HCV nurse specialist or other qualified health care professional 
– this applies to co-located services, as well as ‘solo’ services. Experts at the 
stakeholder event confirmed the importance of helping the service user to 
prioritise further HCV testing. 
1.20 In order to maximise all opportunities to obtain required blood samples, 
train other qualified health care professional (such as community-based 
practitioners) to initiate the conversation about finding suitable veins 
and then to conduct venepuncture on the service user for the HCV PCR 
blood test. This needs to be achieved by providing a comprehensive and 
hands-on training package to other qualified health care staff and new 
HCV nurse specialists, including peer-led learning on the sensitivities when 
drawing bloods from people who inject drugs. Consider specific online 
learning materials, fact sheets or visual illustrations regarding the ‘best’ 
The specific skill of successfully taking blood samples from a service user is 
important, but is part of a wider therapeutic harm reduction with the service 
user, where the main aim of practice and confidence is to make drawing bloods 
appear effortless. Data from NHS Tayside suggest that being skilled at 
venepuncture, and making it seem ‘easy’, alleviates any potentially negative 
emotions on blood drawing (e.g. shame, expected pain) in the service user. 
Experts in the stakeholder groups confirmed that while venepuncture training is 
essential, confidence and practice are vital for a seamless and effortless 
procedure, which should be imparted to other health care professionals to 
ensure an effective HCV testing network.  





and alternative sites on the body to draw bloods from in people who 
inject drugs. 
1.21 Promote the benefits of HCV testing and treatment to service users. This 
could include the provision of posters, leaflets, short films, social media 
posts and visual materials providing personal testimonies of service users 
who completed the HCV treatment. Consider providing information on the 
number of service users successfully tested and treated locally or 
regionally to encourage uptake of HCV testing and treatment. The aim is 
to normalise HCV testing and treatment, as well as reiterate the benefits 
associated with testing and treatment. 
To promote HCV testing and treatment, accessible dissemination of HCV 
information is essential to educate service users in all pathways, and normalise 
HCV testing and treatment among people who inject drugs. Evidence in NHS 
Tayside suggest that many service users were unclear about transmission risks 
and routes, and consequences of HCV if untreated. Experts in our stakeholder 
groups stressed the importance, value and ethics of providing written and 
verbal information about HCV, while the service user stakeholders highlighted 
the power and credibility of information received via peer workers. 
1.22 Provide training on core aspects and the sequence of core aspects in 
setting up the HCV treatment plan for (new) HCV nurse specialists or 
other qualified health care professional. This can be achieved by co-
producing successful treatment plan conversations via peer learning and 
ongoing CPD. As part of the treatment plan conversation, enhance HCV 
nurse specialists’ skills of motivational interviewing to promote the 
treatment and its benefits. This is to facilitate the service user’s 
engagement. 
Consistent adherence to the HCV treatment plan is dependent on the inclusion 
of the service user’s preference of where (e.g. pharmacy), and how they will 
collect their HCV medication (daily, weekly, supervised vs unsupervised). 
Evidence from NHS Tayside demonstrates that HCV nurse specialists ensure 
that the treatment plan is tailored to the service user’s concurrent medications 
(where applicable) and in line with their pharmacy preferences, which was 
positively noted by service users. Experts in our stakeholder groups felt that this 
recommendation may be particularly relevant for other healthcare 
professionals such as doctors (GPs). 
1.23 Co-produce verbal agreements (e.g. behavioural contracts) with service 
users to assist adherence to HCV treatment, depending on the 
relationship between service provider and service user. This should be 
achieved by providing a training package aimed at developing agreements 
and behavioural contracts between staff responsible for any part of HCV 
testing and/or treatment and service users. For example, scripts of ‘good’ 
behavioural contract conversations could be included, informed by 
experienced HCV nurse specialists or other key staff (e.g. pharmacists) 
who use behavioural contracts as part of concurrent OST treatment. The 
aim is to facilitate engagement, HCV treatment completion and 
therapeutic collaboration in a culturally sensitive and constructive 
manner. 
Behavioural HCV contracts or verbal agreements between HCV service 
providers and service users facilitate action planning, collaborative problem 
solving and commitment to complete the HCV treatment. Our analysis from 
NHS Tayside supports verbal agreements or behavioural contracts as a powerful 
means to communicate the importance of treatment engagement and 
completion. Experts at the stakeholder events stressed the importance of 
assessing the suitability of behavioural contracts for each service user, and 
considering the relationship between service provider and service user, as some 
service users may perceive a behavioural contract as stigmatising. 





1.24 Train staff responsible for any part of HCV testing and/or treatment to 
motivate, support and review the service user during HCV treatment to 
facilitate treatment adherence. Staff training can be achieved by co-
producing ‘good’ review and support conversations with experienced staff 
or HCV nurse specialists, and may be particularly relevant for HCV services 
that do not routinely offer new interventions. These conversations should 
include aspects of brief interventions such as motivational interviewing, 
and verbal reinforcements for the service user’s continued adherence to 
the HCV treatment plan. 
Structured positive reinforcement is a known facilitator to motivating service 
user’s adherence and engagement with HCV treatment (e.g. Patel, 2019). 
Evidence from NHS Tayside strongly suggests that staff responsible for any part 
of HCV testing and/or treatment learned the value and benefits of closely 
engaging with the service user to monitor potential side effects and overall 
health and wellbeing during the HCV treatment. Experts in our stakeholder 
groups supported a cross-service collaborative approach in ensuring and 
maintaining HCV engagement and the service user’s wellbeing. 
1.25 View SVR12 testing as an opportunity to promote harm reduction 
services and thereafter adopt a proactive approach to regular follow-up 
testing and continuous harm reduction support. This needs to be 
achieved via training of all staff responsible for any aspect of HCV testing 
or treatment to be flexible and opportunistic in their approach to 
obtaining DBSTs (or alternative biosampling HCV test) post HCV 
treatment, and thereafter as part of ongoing harm reduction and 
recovery. This should include training and assessment of cultural and 
clinical competencies to maintain and utilise the therapeutic relationship 
with the aim of normalising harm reduction, HCV testing and treatment 
(e.g. as part of the verbal agreement, see recommendation 1.23). 
The aim of upscaling HCV testing and treatment across different settings is to 
routinely embed HCV testing (and treatment) within staff’s understandings and 
approaches to harm reduction and recovery. Evidence from NHS Tayside 
suggests that staff were aware of the value and benefits of normalising repeat 
HCV testing for people who inject drugs. Experts in the stakeholder groups 
emphasised the need to consider HCV testing as a routine, ongoing part of 
harm reduction, rather than a separate and conclusive one-off intervention. 
1.26 Implement an HCV Testing and treatment administrative data system. 
This could be achieved through a live HCV database to record service users 
with an antibody test, and to track those with chronic HCV infection (e.g. 
all HCV PCR positives). This database can further be used to facilitate 
routine audits of HCV testing and treatment as part of caseload 
management and care planning. In addition, consider nominating a ‘HCV 
facilitator’ or ‘HCV champion’ in each treatment setting as the main liaison 
contact between HCV nurse specialists and staff in each setting, as well as 
facilitating effective HCV case management and monitoring. This needs to 
be supported by agreeing on national/ regional/ local targets, which are 
endorsed by senior management and upheld by managers in local HCV 
services. 
Routine audits are a reliable method to measure, monitor and plan HCV testing 
and treatment as part of the pathway services. Our evidence from NHS Tayside 
strongly suggests that a live HCV database assists in case management, and is a 
valuable and effective means to identifying gaps in HCV service provision and 
structure. Experts at the stakeholder event noted the benefits of audits and 
having a HCV facilitator or champion in relation to providing general 
information and advice, oversight, information sharing and collating service 
user numbers tested and successfully treated are worthwhile. 





1.27 In addition to recommendations 1.25 and 1.26, ensure a responsive 
system is in place to share information across HCV services and patient 
pathways, for example when a service user disengages from any HCV 
service. Clearly define the processes and procedures involved in HCV care 
transition when a service user diverts from the HCV service, or chooses to 
disengage from the HCV nurse specialist or other qualified health 
professional. This can be facilitated through national data sharing 
agreements across NHS and non-NHS service providers who are involved 
in the patient pathway for the purpose of HCV testing and treatment. 
Maintain awareness of these protocols through supervision, appraisals 
and CPD. 
To enable successful upscaling of HCV services, HCV collaborations must be 
established and formalised across different health care providers. Data from 
NHS Tayside suggest that while different services choose different levels of 
informal or formal agreements, the expectations of staff’s HCV responsibilities 
were consistent. Experts at the stakeholder events emphasised the need to 
clearly determine procedures and information sharing agreements if a service 
user disengages from one service provider but may choose to continue 
engagement with another service provider. 
2.1 Implement an enhanced needle and syringe programme service as part 
of a community ‘hub’ model to providing and promoting HCV testing and 
treatment, and harm reduction. This can be achieved by establishing a 
network of community services and multi-disciplinary agency workers (e.g. 
comprising NHS and third sector such as harm reduction and social 
services) to co-ordinate care, treatment and recovery, to involve peer 
workers as part of the service and to enable co-location of services to 
maximise reaching service users. 
Community pathway hub models are well established networks of focused 
community organisations collaborating to provide care for vulnerable and hard 
to reach populations such as people who inject drugs (Zeigler, Carter, Redding 
et al, 2014). Evidence from NHS Tayside suggests that HCV testing and 
treatment among ENSP service users may be a gateway to recovery and 
reduction in HCV risk behaviours. Experts at stakeholder events emphasised the 
success of the community hub model in Tayside.  
2.2 Establish and share a range of successful communication methods with 
the service user that facilitate follow up for HCV tests, results, and HCV 
treatment, especially to promote regular HCV testing post treatment to 
detect reinfections early for further HCV treatment. Consideration should 
be given to the frequency of reminders and range of viable 
communication methods. 
Reliable and dependable (tried and tested) communication methods to 
facilitate repeat HCV testing and follow-up for HCV testing and treatment are 
essential, especially in ENSP who have access to people who may be actively 
injecting. Evidence from NHS Tayside suggests that staff developed a range of 
communication methods to facilitate timely HCV treatment post testing.  
Experts in our stakeholder group emphasised that repeat contacting via diverse 
channels (letters, phone calls, healthcare colleagues such as pharmacists) were 
helpful in motivating service users to return for their test results. 
2.3 Ensure flexibility in the delivery of the ENSP service model of HCV care 
by upskilling staff responsible for any part of HCV testing and/or 
treatment to engage in an outreach service model under Covid-19 (or 
similar future) restrictions. 
The attraction of offering HCV services within an ENSP is bound to the busy 
service user flow, who wish to collect needle and syringe equipment, or access 
co-located recovery services (if available). While we have no evidence from NHS 
Tayside as our data collection took place pre-Covid, initial impressions suggest 
that ENSP staff who are responsible for any part of HCV testing and/or 





treatment and HCV nurse specialists (or other qualified health care staff) should 
consider shared outreach to test people who inject drugs for HCV, e.g. by 
attending people’s homes, homeless hostels, and drop-in centres. Experts in 
our stakeholder group strongly emphasised that service delivery must be 
flexible, proactive and adjusted to the needs and locations of the service users. 
3.1 Ensure processes such as contractual frameworks, quality standards and 
financial processes for the implementation of HCV testing and treatment 
are in place in pharmacies. This needs to be achieved through the use of 
established procurement systems. 
 
Timely and clear contractual systems can facilitate the implementation of HCV 
testing and treatment in pharmacies by providing guidance and information on 
pharmacy staff’s roles and tasks. Evidence from NHS Tayside suggests that 
financial clarity and transparency is necessary for up-scaling pharmacies to 
provide HCV testing and treatment services. Experts in the stakeholder group 
explained that existing procurement systems should be utilised to facilitate this 
including regular quality assessment and feedback. 
3.2 Enhance training packages on interpersonal skills to include aspects of 
active listening, rapport building and cultural competence for staff 
responsible for any part of HCV testing and/or treatment. Staff should be 
skilled to move between a commercially based relationship (customer and 
supplier) to one that effectively promotes culturally sensitive and wider 
holistic approaches to health and wellbeing including HCV care provision. 
In order to offer HCV testing and treatment in pharmacies, the timing and 
manner with which service users are initially approached is decisive in ensuring 
their engagement. Evidence from NHS Tayside suggests that there is a clear 
need for training to enhance interpersonal skills and use a culturally sensitive 
vocabulary to promote HCV testing and treatment. Experts in our stakeholder 
group agreed that all staff should be able to promote HCV testing and 
treatment effectively and sensitively to facilitate uptake. 
3.3 Train and upskill a sufficient number of pharmacy staff to deliver both, 
HCV testing (DBST) and treatment. This can be achieved via two models, 
dependent on local preference: either train up all staff to be able to 
conduct HCV testing (DBST) and HCV treatment, or at a minimum train a 
small group of key staff who are primarily responsible for conducting HCV 
testing and treatment (including HCV prescribing). Liaise with HCV nurse 
specialist or other qualified healthcare professional if specialist skills for 
venepuncture are required. Training should include regular appraisals of 
competencies and consistency in the delivery of HCV testing and 
treatment. 
Pharmacies are key locations to deliver HCV testing and treatment, with the 
most efficient HCV delivery model being dependent on local resource and 
staffing (e.g. number of consultation rooms). Our analysis from NHS Tayside 
suggests that pharmacists were keen to expand their skills and utilise their 
relationships with service users to deliver HCV testing and treatment; ideally in 
collaboration with a regular in-house HCV clinic to provide specialist skills. 
Experts in our stakeholder group emphasised that upscaling HCV testing and 
treatment in pharmacies was essential, and was part of a wider team effort 
with specialist healthcare staff conducting venepuncture where required.  
3.4 Enhance staff training to include behaviour change competencies to 
facilitate the service user’s HCV treatment completion for staff 
responsible for any part of HCV testing and/or treatment. Training 
Behavioural contracts or verbal agreements between pharmacists and service 
users facilitate action planning, collaborative problem solving and commitment 
to complete the HCV treatment. Our analysis from NHS Tayside supports the 





packages should include issues such as using behavioural contracts with 
service users (e.g. requesting a verbal commitment to treatment 
completion) because most service users collect their HCV prescriptions 
from pharmacies, and are therefore in regular contact with pharmacy 
staff. For example, training scripts of effective conversations could be 
included, informed by prior experience of HCV nurse specialists or 
pharmacy staff. The aim is to facilitate engagement, HCV treatment 
completion and therapeutic collaboration in a culturally sensitive and 
constructive manner. 
idea of behavioural contracts or verbal agreements as a powerful means to 
secure treatment engagement and completion. Some experts in our 
stakeholder groups felt that this recommendation was unsuitable in a busy 
pharmacy setting, while other stakeholders confirmed that good relationships 
between service users and pharmacy staff could be utilized and enhanced to 
support HCV treatment engagement. 
3.5 To maximise the uptake of HCV testing and treatment, HCV nurse 
specialists should develop and share an accessible list of potential HCV 
service users who receive opiate substitution therapy. This needs to be 
achieved by pharmacies collaborating closely with the HCV nurse 
specialist(s) to identify and track eligible OST service users. 
Developing, updating and sharing a list of eligible OST service users enables 
pharmacy staff to focus on discreet, task-based HCV activities. Evidence from 
NHS Tayside suggest that pharmacy staff greatly value working from a list of 
eligible OST service users who they specifically target to promote HCV testing 
and treatment. Experts at the stakeholder events emphasised that all OST 
service users should be offered repeat HCV testing, and that monitoring 
mechanisms such as a live HCV database assist. 
4.1 Implement a standardised opt-out HCV testing model in all community 
drug treatment services. Support drug treatment staff to prioritise the 
promotion of HCV testing and treatment to the service user. This needs 
to be achieved by enabling drug treatment staff to provide person-centred 
care while helping the service user to (re-) prioritise HCV engagement 
among competing needs. 
The prioritisation of HCV testing and treatment is essential, considering that 
drug treatment services address a wide range of service users’ needs and 
issues. Evidence from NHS Tayside highlights that drug treatment services are 
user-led, and operate an opt-out HCV testing model, therefore focussed efforts 
to prioritise and re-prioritise HCV testing and treatment for the service user are 
required. Experts at our stakeholder event highlighted balancing the service 
user’s needs versus timely HCV testing and treatment. 
4.2 Co-ordinate drug treatment and the HCV care pathway to facilitate 
service user engagement, timely HCV testing and treatment and regular 
contact via shared outreach appointments and home visits. This includes 
physically collecting service users for their HCV appointments, utilising 
digital technologies as part of HCV consultations, as well as providing HCV 
testing and treatment within the service user’s home. This needs to be 
achieved by formally setting up a service agreement on utilising existing 
outreach structures in the drug treatment service. 
Allowing HCV nurse specialists or other qualified healthcare professionals to 
‘piggy-back’ onto existing outreach and home visit structures in drug treatment 
services is an efficient and effective way of engaging with, testing and treating 
hard to reach people who inject drugs, who may not be able to attend HCV 
clinics. Evidence from NHS Tayside suggests that this is a valuable means to 
providing HCV care in rural areas. Experts in our stakeholder group viewed this 
as a viable approach, and they agreed that a formal cross-service agreement 
was a necessity. 





5.1 Implement a standardised opt-out HCV testing model in all prison 
services. As a routine part of admission procedures and processes to 
prison, offer BBV testing (including HCV testing) to all individuals entering 
custody regardless of their legal status (i.e. remand, sentenced or those 
awaiting sentencing).  Support prison staff at admission to promote and 
prioritise HCV testing as part of the admission procedure. 
Opt-out HCV testing is a routine implemented service at Scottish prisons with 
good uptake, with governmental endorsement and guidance (Sexual Health and 
Blood-Borne Virus Framework, Scottish Government, 2015). Evidence from NHS 
Tayside suggests that the offer and uptake of opt-out HCV testing at prison 
admission is good, however HCV test completion may require follow-up post a 
person’s admission, i.e. in residential halls. Experts at our stakeholder events 
confirmed the importance of opt-out HCV testing at admission to prison, with 
further options of HCV testing and treatment for those who declined or did not 
attend HCV testing in prison. 
5.2 Ensure effective and formalised protocols are in place for sharing clinical 
information among those staff responsible for any part of HCV testing 
and/or treatment inside prison, between prisons, between the prison and 
specialist HCV services. This is to ensure HCV continuity of care for service 
users including those transferring between prisons and transitioning to the 
community. 
Effective HCV testing and treatment is dependent on providing continuity of 
HCV care for the service user across different settings. Evidence from NHS 
Tayside indicates that an effective clinical information system must be in place 
in each prison for staff responsible for any part of HCV testing and/or 
treatment. The system needs to accommodate the transfer of service users 
between prisons and release from prison. Close liaison between NHS staff (in 
Tayside: HCV specialist nurse) and prison staff was essential in particular when 
service users were released or transferred to another prison.  Experts in our 
stakeholder groups suggested the need and value for national data sharing 
agreements across NHS and non-NHS service providers. 
5.3 Promote HCV testing and treatment via a dedicated prison-based 
healthcare facilitator. This needs to be an individual with excellent 
interpersonal skills to establish relationships, and with privileged access to 
residential officers, (eligible) service users in prison and delegated 
healthcare and HCV staff. For example, this could be a health care worker 
or a residential officer.  Consider recruiting more than one healthcare 
facilitator to cover potential staff absence. Provide essential training to the 
health facilitator(s) on HCV engagement, HCV testing and treatment.  
 
Upscaling HCV treatment in prisons is likely to be enhanced by a dedicated 
healthcare facilitator whose role includes to promote and support HCV testing 
and treatment among service users and prison staff. Evidence from NHS Tayside 
suggests that the introduction of a HCV-specific facilitator, who has good 
relationships with prison staff, the HCV nurse specialists and the (eligible) 
service users, has a positive impact on the uptake of HCV testing and 
treatment. Experts in our stakeholder groups confirmed the beneficial impact 
of a dedicated prison-based healthcare facilitator (to avoid HCV stigmatization), 
and they highlighted the benefits of training up several facilitators to cover for 
potential sickness or leave. 
5.4 Ensure all HCV testing methods are available including oral swabs, which 
could be utilised in private areas in the residential prison halls. Oral 
swabs are less expensive, almost as accurate as DBST and more 
Successful promotion and engagement with HCV testing and treatment among 
service users is dependent on a flexible, opportunity-driven and culturally 
sensitive service model. Our data from NHS Tayside evidences the success of 





convenient to conduct for both, service users and those staff that use oral 
swabs. While oral swabs can only be used to test for the presence of HCV 
antibodies, they are suitable with HCV low risk populations and when 
testing occurs outside clinic environments such as in residential prison 
halls. This needs to be achieved by restructuring HCV service provision to 
maximise contact at times when people residing in prison are available. 
HCV testing via oral swabs by bringing the service to people in residential halls 
in prison, thereby removing the challenges associated with accessing a health 
care centre in the prison. Some expert stakeholders questioned the efficacy of 
oral swabs, while others confirmed the utility of oral swabs in reaching non-
attendees at clinics and as a motivating factor to engage people residing in 
prison in further HCV testing and treatment. 
5.5 In addition to recommendation 5.2, provide training on how to preserve 
confidentiality when communicating with people residing in prison 
about HCV and thus avoiding possible stigmatisation. Consider liaising 
with the service user via the HCV facilitator, peer workers, or residential 
officers (provided the service user gave consent). 
Service users in prison may require additional support during their HCV testing 
and treatment due to fear of stigma. Evidence from NHS Tayside strongly 
suggests that service users are distressed and worried about possible 
stigmatisation from others (people residing in prison and staff) when they 
receive letters about HCV appointments or HCV test results in prison, e.g. due 
to lack of privacy when sharing a cell. Experts in our stakeholder groups 
suggested service users should be given options of how they would like to 
receive information about their HCV testing and treatment outcomes. 
 





Appendix 2 Methods 
 
Prior to data collection, we conducted informal interviews with experts (n=4) on the background and 
development of the HCV treatment care pathway in each setting (enhanced needle syringe 
programmes, pharmacies, drug treatment clinics and prison). We identified the key steps in each 
pathway, and mapped out who did what to whom, when, where and in what sequence. We sense-
checked these pathway maps with experts to ensure that we had an accurate understanding of all 
actors, activities and the sequence of actions. These pathway maps were used to guide discussions in 
subsequent data collection.  
 
We conducted qualitative interviews and focus groups with 40 HCV service providers including local 
peer workers, and we worked with peer researchers to interview 31 service users across the four 
treatment pathways. We identified the facilitators and barriers to each key step in the relevant 
treatment pathway. All facilitators and barriers were then coded using the behaviour change wheel, 
including the COM-B model, the Theoretical Domains Framework and Intervention Function to 
determine the associated and specific behaviour change techniques to underpin specific and 
evidence-based recommendations for HCV upscale of services. All behaviour change coding and initial 
recommendations were conducted by the junior researcher and double-checked by one or both of 
the senior qualitative researchers, who also sense-checked the sensitivity and placement of 
recommendations within the wider HCV delivery landscape. 
 
We identified the top 8-12 recommendations for each pathway and presented these for discussion to 
key stakeholders in each pathway. Stakeholders included frontline staff, clinical leads, managers and 
commissioners as well as service users. All stakeholders were invited to apply the APEASE criteria to 
each recommendation and then decide whether to ‘keep’, ‘kill’, ‘add’ or ‘amend’ a recommendation. 
The APEASE criteria are a set of criteria to guide context-specific decisions on an intervention content 
or delivery, and refer to acceptability, practicability, effectiveness, affordability, safety and equity 
(Michie, Atkins & West, 2014). In this way, stakeholder events were utilised to co-produce highly 
relevant, useful and pathway-specific recommendations from the qualitative data and expert input. 
The outputs from stakeholder events were merged with the specific pathway recommendations to 
generate the final set of recommendations in the manual. Where stakeholders were unable to attend 

























Appendix 3 DBST guidelines as a template of SOP/ guidelines 
 
NHS Tayside 
Tayside Substance Misuse,  
Dry Blood Spot Testing 
Standard Operating Procedure 
 Procedure Name: Dry Blood Spot Testing 
 
Date of Issue:  11th May 2011 
Procedure No:  Clinical 001 
Page 40 of 2 
Supersedes: This is a New SOP 
 
A. Background 
Dry Blood Spot testing is a method for screening for a Blood Borne Virus. In Constitution 
House and the Cairn Centre this will mainly be screening for Hepatitis C. From the data 
gathered to date, the prevalence is 30% – 35% within TSMS population – which means 1 in 




This procedure states the method and process for undertaking BBV testing for Hepatitis C 
as well as systems for monitoring frequency of testing. 
(i) Tayside Substance Misuse Service (TSMS) 
TSMS comprises the following clinical services: 
- Drug Service (Angus, Dundee and Perth & Kinross) 
- Alcohol Service (Angus, Dundee and Perth & Kinross) 
- Transition Service (Dundee) 
- & Partnership Projects: 
- Drug Treatment & Testing Order Service (DTTO) 
- Choice Project (Dundee) 
- New Beginnings (Dundee) 
- Tayside Arrest Referral Service 
This SOP applies only to all of TSMS services: 
 
 (ii) Roles and Responsibilities 
- All clinical staff seeing clients for treatment need to comply with this SOP. 
- All clinical staff need to read and understand this SOP 
- All Clinical Leads and Clinical Team Managers need to ensure that this SOP is 
incorporated as part of Induction for new members of staff, who join TSMS. 
 





C. Competencies Required. 
All staff will have undergone pre and post-test discussion training in relation to BBV testing 
as well as local training in using the dry blood spot testing technique. 
 
D. Patients Covered. 
All service users presenting to TSMS will be offered testing. 
 
E. A reference copy of this SOP will be kept in a designated and easily accessible file. 
Procedure:  
(1) The Staff member will explain the procedure for the test 
(2) The Staff member will ask the client to sign the consent form. Completed consent 
form need to be given to Brian Stephens for database purposes – Do NOT send 
consent form to the Laboratory 
(3) The Staff member will be expected to follow the BBV MCN Guidelines, which has 
been written by the Senior Virology Consultant within Appendix 1, which include the 
following: 
- Step-by-step guide to carrying out the test 
- Information about interpreting results  
- Making queries to the laboratory 
(4) Once the procedure has been completed, the Staff member will place the card with 
the dried blood spots into the request form’s bag. Seal the bag with the self-adhesive 
strip. The sealed bag should be placed in the designated area for collection to go to 
Medical Microbiology. 
(5) Details on how and where the test results will be given should be arranged prior to 
the patient leaving the appointment.  
(6) Enter details of offer of test, client’s consent or decline to test, and procedure carried 
out & follow-up arrangements in contemporaneous notes or in MiDIS (post 
implementation) 
This SOP will be monitored via Monthly reports and activity analysis. 
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Date: 11/05/2011                                           Date:  11th May 2011  
 
 





Appendix 4 Acknowledgements 
 
The development of these recommendations are due to the input, patience and effort from many 
individuals. We would like to thank all research participants – service users and service providers in 
NHS Tayside – for their time and sharing their experiences with us. We would like to thank the 
Hepatitis C specialist nursing team for their invaluable support, guidance and assistance in recruiting 
service users and providing feedback on versions of the recommendations. Likewise, we would like to 
extend our thanks to the peer researchers at the Scottish Drugs Forum, and the multiple stakeholders 
(service providers, service users and peer workers) who engaged with the recommendations and 
helped us to make them future-facing and context sensitive. In particular, we would like to 
acknowledge the contributions from Cliodhna Lane, Billy Hamilton, Wendy Mitchell, Claire Kofman, 
Fiona Raeburn, Mina O’hara, Erica Peters, Lisa Allerton, Lindsey Stronach, Hilda Stiven, Petra Wright, 
Julie Craik, Peter Bramley, Lynn Cooper, Ewen Stewart, Lisa Turnbull, Pauline Dundas, Kim MacBeth, 
Leon Wylie, Gillian Baillie-Smith, Fiona Cowden and Danny Kelly.  
 
 
 
